Pro Medicus share price dropped as much as 5.8% on Friday, one of the ASX 200’s heaviest falls on a day the index itself was higher. ResMed fell Thursday. Rio Tinto fell Wednesday and Thursday on a broker downgrade. Line the three up and only one looks like a sell-off the market has earned.
Market context: green index, red healthcare
The S&P/ASX 200 was up about 0.5% by midday Friday 10 July 2026, on track to snap a four-day losing streak, though still down roughly 0.4% for the week. The gain masked a split. Materials rose about 2.3%, bouncing after falling as much as 14% since 17 June. Healthcare fell about 1.9%, pulling back after rallying almost 25% since its nine-year low on 3 June. Pro Medicus, Wisetech and Xero led tech-heavy names lower
Pro Medicus share price: a real question, not solved by one bad day
Pro Medicus (ASX: PME) shares were trading at $200.44 by early afternoon Friday, down 4.74% on the session, touching intraday lows that put the fall as high as 5.8% against Thursday’s close. That is a heavy move with no company announcement attached to it. Kalkine’s own coverage was explicit: without a specific announcement, the fall is hard to attribute to one cause, and is more likely sector rotation and profit-taking after a sharp run.
That run was real. Pro Medicus fell as much as 60% from its 2025 peak and dropped a further 22% in one session in February 2026, despite record first-half revenue of $124.8 million, up 28.4%, and underlying profit up 29.7% to $90.7 million. The market’s concern was never the numbers. It was whether AI tools for reading medical scans eventually compete with, rather than run on top of, Pro Medicus’s cloud radiology platform. That question is unresolved today exactly as it was in February.
What has changed is the price paid to own that uncertainty. Morgans lifted its target to $230 in early July as the stock rallied off its lows, trimming its rating to Accumulate on valuation grounds, not a change of view on the business. At $200.44, that target still implies roughly 15% upside (Investor Standard calculation). The stock remains down about 32% over the twelve months to 7 July 2026. Friday’s drop reads more as profit-taking on a fast rally than fresh evidence the bear case just won.
ResMed: the pullback with the weaker excuse
ResMed (ASX: RMD) fell 2.82% to A$30.31 on Thursday 9 July 2026, from a previous close of A$31.19, on volume above its average turnover. Again, no company announcement was attached to the move. What did happen that week was a divestment, not a downgrade: ResMed agreed on 7 July 2026 to sell its MatrixCare software business, a non-core, lower-margin unit, sharpening focus on its core sleep and respiratory device franchise.
ResMed’s fundamentals have not been the problem. Second-quarter FY26 revenue rose 11% to US$1.42 billion and net income rose 14%, and the stock was still up about 18% since its 3 June low even after Thursday’s fall. Morgans holds a Buy rating with a $41.72 target, noting the stock had de-rated to about 16 times forward earnings despite double-digit forecast growth. Against the $30.31 close, that implies close to 38% upside (Investor Standard calculation). A decade-low multiple, double-digit growth, a distraction just sold off, falling on a day with no news: that looks like sector-wide selling catching a name that did not need to be sold.
Rio Tinto: the one downgrade with a stated reason
Rio Tinto (ASX: RIO) fell 3.13% on Wednesday 8 July and a further 3.72% intraday on Thursday 9 July to $157.75, among the ASX 200’s largest fallers both days. Unlike the healthcare names, this one has a dated trigger. Morgan Stanley downgraded Rio Tinto and Deterra Royalties to Underweight in a Thursday sector note, calling lower commodity prices and pressure on producer share prices simply “par for the course” after an 18-month uptrend, with its preference now sitting with copper and uranium over diversified miners.
That is a valuation call, not a call that Rio Tinto’s business has deteriorated. The Materials index bounced 2.3% on Friday as the sector found a floor. Rio’s fall is the most defensible of the three because a named broker, on a stated date, gave a specific reason grounded in valuation after a long run, the same logic that arguably applies to the other two but was never spelled out for either.
| Company | The fall | Stated cause | Our read |
|---|---|---|---|
| Pro Medicus (PME) |
-4.74% to A$200.44 (10 Jul), intraday lows near -5.8% | None confirmed; sector rotation after a sharp rally | Real AI-margin question, unresolved either way; price now below broker target |
| ResMed (RMD) |
-2.82% to A$30.31 (9 Jul) | None confirmed; MatrixCare divestment same week | Weakest case for the sell-off; growing double digits at a decade-low multiple |
| Rio Tinto (RIO) |
-3.13% (8 Jul), -3.72% intraday (9 Jul) to A$157.75 | Morgan Stanley downgrade to Underweight, valuation-led | Most defensible fall; a named, dated, stated reason |
Figures are as cited by source and date. Percentage falls are as reported for the session referenced; some are intraday reads rather than confirmed closing prints. Upside implied by broker targets are The Investor Standard calculations from the cited target and latest traded price, not broker figures.
What’s next
Watch whether Pro Medicus and ResMed keep falling without an announcement. If they do, that would point to index-level rotation rather than a one-day wobble.
For Rio, the key signal is whether Friday’s Materials bounce extends or the downgrade keeps capping the stock.
Pro Medicus’s FY26 result and commentary on AI-native imaging rivals will matter most for the longer-term read.
For ResMed, watch whether MatrixCare proceeds fund buybacks rather than masking softer device demand. For Rio, watch whether copper and uranium keep outperforming diversified miners, as Morgan Stanley expects.
If Pro Medicus’s FY26 result shows contract growth slowing, the bull case weakens regardless of today’s share price.
ResMed’s case fails if device volumes, not just valuation multiples, start missing.
Rio’s downgrade could prove early if copper and iron ore hold up better than expected. A valuation call is not the same thing as a demand call.
Investor takeaway
Three ASX names fell this week and the size of each fall said little about which one deserved it. Pro Medicus carries a live, unresolved margin question, but sits below a broker target set after the rally, not before it. ResMed’s fall came with the weakest excuse: no news, a supportive divestment, fundamentals still growing. Rio Tinto is the only one with a broker willing to put a name and a date on the call. When a sector gives back a rally at once, trust the market on the stock that fell for a stated reason. The other two are worth a second look.